Genocea Biosciences, Inc. (GNCA) Stock: Is This Biotech Stock Worth Your Time?

0

Genocea Biosciences, Inc. (GNCA) is headed up in the market today. The stock, focused on the biotechnology industry, is currently priced at $2.64 after gaining 9.05% so far today. When it comes to biotech companies, there are several aspects that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines surrounding GNCA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-30-19 01:13PM Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More
Sep-27-19 08:00AM Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference
Sep-18-19 09:31AM Buy These 7 Small Drugmakers to Boost Your Portfolio’s Health
Aug-30-19 08:00AM Genocea to Present at September Healthcare Conferences
Aug-24-19 01:46PM 10 Biopharmaceutical Companies Trying To Cure Cancer

Nonetheless, any time investors are making an investing decision, investors should look into far more than news, this is especially the case in the speculative biotech space. Here’s what’s happing when it comes to Genocea Biosciences, Inc..

Recent Movement Out of GNCA

While a move up on a single session, like the move that we’re seeing from Genocea Biosciences, Inc. may lead to excitement in some investors, that by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s always smart to look at trends for a period longer than a single trading day. When it comes to GNCA, here are the movements that investors have seen:

  • Past Seven Days – Throughout the past five trading sessions, GNCA has seen a price change amounting to -14.18%.
  • Past Month – The monthly returns from Genocea Biosciences, Inc. works out to -33.15%.
  • Quarterly – In the past three months, the stock has generated a return on investment of -31.44%
  • Past Six Months – Throughout the past 6 months, we’ve seen a change that works out to -56.87% from the stock.
  • This Year So Far – Since the the last trading session of last year GNCA has generated a ROI of 5.47%.
  • Annually – Finally, throughout the last full year, investors have seen a change amounting to -61.22% from GNCA. Throughout this period of time, the stock has traded at a high price of -76.60% and a low price of 17.81%.

Crucial Ratios

Looking at various ratios associated with a stock can give prospective investors a look of just how risky and/or rewarding a stock pick might be. Here are some of the key ratios to look at when looking at GNCA.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the stock is going to go down. Across the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, when it comes to Genocea Biosciences, Inc., the stock’s short ratio is 2.06.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure If a company is able to cover its debts when they mature using quick assets or current assets. Because many biotech companies rely heavily on the continuation of support from investors, these ratios can look damning. Nonetheless, quite a few better companies in the biotechnology sector come with strong quick and current ratios. As far as GNCA, the quick and current ratios work out to 6.00 and 6.00 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the price of shares. In this particular case, that ratio works out to 2.46.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotech stock, this is a very important ratio to consider. In this case, the cash to share value is 2.17.

What Analysts Think About Genocea Biosciences, Inc.

While it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their analysis to validate your own thoughts when it comes to making an investment decision in the biotechnology sector. Here are the most recent moves that we’ve seen from analysts with regard to GNCA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-08-19 Resumed Stifel Buy $13
Mar-01-19 Reiterated Needham Buy
Feb-06-18 Upgrade Needham Hold → Buy $3
Sep-27-17 Downgrade Needham Buy → Hold
Sep-26-17 Downgrade Stifel Buy → Hold $15 → $2.50

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in GNCA, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 57.00% of Genocea Biosciences, Inc.. Nonetheless, it is important to mention that the ownership held by institutions has changed in the amount of 0 in the last 3 months.
  • Insider Holdings – as it relates to insiders, insiders of the company currently hold 11.14% of the company. Their ownership of the company has changed in the amount of 0 in the past 3 months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 27.00M shares of Genocea Biosciences, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, GNCA has a float of 24.59M.

I also find it important to take a look at the short percent. Think about it, when a high portion of the float available for trading is sold short, the overall feeling in the market is that the equity is headed for a steep decline. When it comes to GNCA, the percentage of the float that is shorted currently sits at 1.24%. Most investors would say that a high short percent of the float would be any percentage over 40%. However, I’ve calculated that a short percent of the float over 26% is likely a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from GNCA in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands at the moment, analysts have expectations that the company will create EPS coming to a total of -1.72, with -0.46 to be reported in the next financial report. Although this data is not earnings driven, because we are talking about analysts, GNCA is currently rated a 1.50 considering a scale that ranges from 1 to 5 where 1 is the poorest possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the last half decade, Genocea Biosciences, Inc. has reported a movement in sales volume that comes to a total of 0. EPS through the last half decade have experienced a change of 23.70%.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is commonly represented in the world of humans, GNCA has created a change in earnings that amounts to -2.00%. Genocea Biosciences, Inc. has also experienced movement when it comes to sales in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings play an important role in my ability to learn. Sure, I can look through social trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here